Cancer Breakthroughs 2020 Milestone: NantWorks Announces NantCare Oncology Solutions, A Technology Support Platform for Community Oncology Practices in the Oncology Care Model (OCM)

New England Cancer Specialists, the largest community oncology practice in Maine with approximately 50,000 visits per year to adopt the QUantum Immuno-Oncology Lifelong Trial (QUILT) program, GPS Cancer™ and Cloud Infrastructural support

BOSTON, Mass. – October 26, 2016 – NantCare, a member of the NantWorks family of companies responsible for operationalizing the Cancer Breakthroughs 2020 and QUILT programs, today announced its active engagement with community oncology practices by providing a combination of technology, access to clinical trials and administrative support to optimize community oncology practices’ compliance in the Oncology Care Model (OCM).

The Center for Medicare & Medicaid Innovation (CMS Innovation Center) is developing new payment and delivery models designed to improve the effectiveness and efficiency of specialty care. Among those specialty models is the Oncology Care Model, which aims to provide higher quality, more highly coordinated oncology care at the same or lower cost to Medicare. The goal of OCM is to utilize appropriately aligned financial incentives to enable improved care coordination, appropriateness of care and access to care for beneficiaries undergoing chemotherapy.

The NantCare OCM solutions bring sophisticated resources and technologies to assist community oncology practices to more efficiently and effectively comply with the administrative and clinical requirements of the CMS’s OCM – resources that are often otherwise available only to large cancer institutions.

Today, 85 percent of oncology care is provided in the community oncology setting and only about three percent of all oncology patients enter into a clinical trial. NantCare’s work to support community oncology practices aims to change that by facilitating practices’ participation in QUILT Trials and by making it easier for patients to participate in clinical trials by not having to travel long distances to major cancer centers for care.

“Our work with community oncology practices opens up the possibility that patients can get access to sophisticated QUILT Trials in the community setting,” stated Carla Balch, President of NantCare. “QUILT can be a vibrant part of the Oncology Care Model; and the innovative approach of QUILT is uniquely well-suited for community oncology. Dr. Soon-Shiong has always been very supportive of the community setting and we believe it’s our priority to do all we can to empower community oncologists with the most advanced science and technology resources available.” 

“We, as community oncologists, today find ourselves in an interesting position as disruptors in a changing healthcare environment,” said Tracey F. Wiseberg MD, President of New England Cancer Specialists. “We can provide often higher quality oncology services at lower costs. Administrative, technical and clinical trial support afforded by our partnership with NantCare will enable patients to receive 21st century immunotherapy medicine locally, and for practices like ours, to participate in the innovative Oncology Care Model launched by CMS.” 

NECS, the largest community practice in Maine with over 3,000 new patients with approximately 50,000 cancer patient visits a year, will receive support which will be made available to all OCM practices including:

  • Real-World Big Data Infrastructure (Terabyte Speed Fiber)
  • Real-Time Next Generation Bioinformatics (Super Computing)
  • HIPAA-Secured Cloud (Distributed Storage)
  • Immuno-Oncology Translational & Basic Science (Cutting Edge Science)
  • Access to Novel Immuno-Oncology Molecules Transcending the Innate & Adaptive Immune System (60 Novel Agents)
  • Cutting-Edge Clinical Trials Combining Novel Novel Agents Across all Tumor Types (Regulatory & Clinical Trial Support)
  • Next-Generation Certified Clinical Immuno-Oncologists with Knowledge of 21st Century Immuno-Oncology (Next Generation Clinical Scientists)

Some of the resources provided by NantCare include decision-support with near real-time bioinformatics and evidence-based protocols that enable the clinician to potentially make more optimal treatment decisions while understanding the economic impact of the treatment, especially as the treatment choices relate to nationally recognized guidelines and clinical trials (including Cancer Breakthroughs 2020 QUILT Trials). Trial Match provides clinical trial matches for patients (including molecular and proteomic data) and an overview of the patient population at the practice, which allows NantCare to open trials that match the overall patient population of each practice. Ordering of GPS Cancer is enabled through physician’s electronic medical records or directly through a convenient web portal. Additionally, the National Tumor Board is available to support any physician ordering GPS Cancer.

NantCare provides a perfect pairing of solutions that enable higher quality care and access to clinical trials for improved outcomes for patients receiving oncology care in the community setting.

About NantWorks

NantWorks, LLC, founded by renowned physician scientist and inventor of the first human nanoparticle chemotherapeutic agent Abraxane®, Dr. Patrick Soon-Shiong, is the umbrella organization for the following entities: NantHealth, NantOmics, NantBio, NantCell, NantPharma, NantVentures and NantCloud. Fact-based and solution-driven, each of NantWorks’ division entities operates at the nexus of innovation and infrastructure. The core mission of NantWorks is convergence and a systems approach to human biology: to develop and deliver a diverse range of technologies that accelerates innovation, broaden the scope of scientific discovery, enhance ground-breaking research, and improve healthcare treatment for those in need. NantWorks is building an integrated fact-based, genomically and proteomically -informed, personalized approach to the delivery of care and the development of next generation diagnostics and therapeutics for life threatening diseases such as Cancer, Infectious Diseases and Alzheimer’s. For more information please ‎www.nantworks.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

 

About NantCare Oncology Solutions

The NantCare OCM solutions bring sophisticated resources and technologies to assist community oncology practices to more efficiently and effectively comply with the administrative and clinical requirements of CMS’s Oncology Care Model – resources that are often otherwise available only to large cancer institutions. ‎ This support, to be made available to all OCM practices will include:

  • Real World Big Data Infrastructure (Terabyte Speed Fiber)
  • Real-Time Next Generation Bioinformatics (Super Computing)
  • HIPAA Secured Cloud (Distributed Storage)
  • Immuno-Oncology Translational & Basic Science (Cutting Edge Science)
  • Access to Novel Immuno-Oncology Molecules Transcending the Innate & Adaptive Immune System (60 Novel Agents)
  • Cutting Edge Clinical Trials Combining Novel Novel Agents Across all Tumor Types (Regulatory & Clinical Trial Support)
  • Next-Generation Certified Clinical Immuno-Oncologists with Knowledge of 21st Century Immuno-Oncology (Next Generation Clinical Scientists

 

About Cancer Breakthroughs 2020

The Cancer Breakthroughs 2020 program is one of the most comprehensive cancer collaborative initiative launched to date, seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. This initiative aims to explore a new paradigm in cancer care by initiating randomized Phase II trials in patients at all stages of disease in 20 tumor types in 20,000 patients within the next 36 months. These findings will inform Phase III trials and the aspirational breakthroughs to develop an effective vaccine-based immunotherapy to combat cancer by 2020. For more information, please visit www.cancerbreakthroughs2020.org and follow @Cancer2020 on Twitter.

 

About GPS Cancer™

GPS Cancer™ is a unique, molecular profile analysis available through NantHealth. GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry, providing oncologists with a comprehensive molecular profile of a patient’s cancer and an assessment of protein pathway function to inform personalized treatment strategies. GPS Cancer scanning is conducted in CLIA-certified and CAP-accredited laboratories, and is a key enabler for Cancer Breakthroughs 2020, the world’s most comprehensive cancer collaborative initiative seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. For more information, visit www.gpscancer.com and www.cancerbreakthroughs2020.org.

 

Press Contact:

Dorit Baxter

NantHealth

401-871-0734

Dbaxter@nanthealth.com